FULVESTRANT
Recurrent Uterine Corpus Carcinoma
Mayo ClinicSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Recurrent Uterine Corpus Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib City of Hope Medical Center | Phase 2 | B |
(+)-VINCRISTINE National Cancer Institute (NCI) | Phase 2 | B |
Irinotecan National Cancer Institute (NCI) | Phase 2 | B |
Letrozole Mayo Clinic | Phase 2 | B |
Zoladex Mayo Clinic | Phase 2 | B |
View all 21 →
Same molecule, other indications
FULVESTRANT is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →